METUPUK will advocate with life science companies to increase the number of MBC trials to a level that will reflect the proportion of MBC patients within the breast cancer population and encourage the recognition of the real potential to extend and save lives.

METUPUK will identify and communicate with life science companies to influence ratios of trial funding to reflect the proportion of MBC patients within the breast cancer population.

METUPUK will monitor to what extent life science companies’ clinical trials and treatments align with Cancer Outcomes and Services Dataset (COSD) v8.0 Data and outcomes and will challenge non-alignment.


METUPUK will work to make breast cancer trials more easily accessible to MBC patients.

METUPUK will encourage and promote the working collaboration of breast cancer charities in order to provide an equitable and improved trial system for all people diagnosed with MBC; encouraging the creation of a universal trial access portal for patients.


METUPUK will lobby regulatory authorities to significantly hasten the drug approval process for all new MBC drug treatments.

METUPUK will encourage and promote the working collaboration of all key stakeholders (i.e., NICE, NHS and pharmaceutical companies) to co-operate meaningfully to reduce the timescales for treatment access.


METUPUK will work with work with all stakeholders to secure broad patient access to new innovative treatment regimes.

METUPUK will encourage and promote the working collaboration of all key stakeholders to ensure swift access to new innovative treatments.


METUPUK will work to maximise the application of technological advances to improve collation and analysis of specific datasets for MBC and encourage medical decision-makers to use the information to better inform treatment decisions.

METUPUK will work collaboratively with the key stakeholders to guarantee revolutionary new technologies are implemented to improve medical decisions for patients.